Liver Fibrosis Treatment Market| Coherent Market Insights - PowerPoint PPT Presentation

View by Category
About This Presentation

Liver Fibrosis Treatment Market| Coherent Market Insights


Read here the latest updates on the Liver Fibrosis Treatment Market published by the CMI team. – PowerPoint PPT presentation

Number of Views:2
Date added: 15 September 2020
Slides: 13
Provided by: adwaitcoherent


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Liver Fibrosis Treatment Market| Coherent Market Insights

Coherent Marketing Insights
  • Market Research Business Consulting Services
  • https//
  • Covid-19 Impact Tracker

  • Liver Fibrosis Treatment Market, by Treatment
    Type (Peroxisome Proliferator-activated Receptors
    (PPAR)-alpha agonist, ACE Inhibitors,
    Hepatotropic Drug, and Others), by Condition
    (Chronic Liver Diseases, Hepatitis C, and
    Nonalcoholic Steatohepatitis), by End User
    (Hospitals, Specialty Clinics, and Others), and
    by Region (North America, Latin America, Europe,
    Asia Pacific, the Middle East, and Africa) -
    Size, Share, Outlook, and Opportunity Analysis,
    2018 2026
  • The global liver fibrosis treatment market size
    is expected to witness a CAGR of 10.8 over the
    forecast period (2018 2026) reaching a value of
    US 28.1 billion in 2026.

  • Liver fibrosis is characterized by repeated or
    continuous damage to liver resulting in an
    abnormally large amount of scar tissue in the
    liver. Fibrosis does not show any symptoms,
    however severe scarring results into cirrhosis,
    which further leads to cause symptoms. To detect
    the severity of disease, healthcare professionals
    conduct blood and imaging test, followed by liver
    biopsy, if required. In the possible treatment
    options for liver fibrosis, healthcare
    professionals focus on treating the cause, which
    often stops and slowdowns further scarring of
    liver and results in improvement of condition.
    The possible treatment options for liver fibrosis
    include use of antiviral drugs, removal or
    dissolve of a blockage in the bile ducts,
    lifestyle changes such as lower consumption of
    alcohol, control regime for obesity and
    overweight, and controlling blood sugar lipid
    levels in people with nonalcoholic fatty liver.
  • Furthermore, research funding by various private
    research organizations to conduct research
    related to development of treatment for liver
    fibrosis and other fatty liver disease is
    expected to spur growth of liver fibrosis
    treatment market. For instance, in August 2018
    professor from College of Science at Virginia
    Tech and Department of Pharmacology at the
    University of Virginia received US 400,000 grant
    from the Virginia Biosciences Health Research
    Corporation (VBHRC) with US 800,000 matching
    funds from Continuum Biosciences, Inc. This grant
    along with matching funds will help researchers
    to develop drugs to treat nonalcoholic
    steatohepatitis (NASH).

  • Global Liver Fibrosis Treatment Market Value (US
    Mn), by Region, 2026

  • Growing Research and Developments (RD)
    Activities and New Developments for Liver
    Fibrosis Treatment are expected to Augment Market
  • Liver fibrosis results from various chronic
    injuries and it often progresses to liver
    cirrhosis, liver failure, portal hypertension,
    and hepatocellular carcinoma. Moreover, liver
    transplantation is only treatment available for
    advanced stage liver fibrosis. Therefore, new
    treatment strategies are currently in clinical
    development stages to treat the liver fibrosis.
    These treatment option include inhibition of
    hepatic injury, inhibition of activation of
    Hematopoietic Stem Cells (HSCs), and inhibition
    of proliferation of HSCs, inhibition of
    deposition of type I collagen and proliferation
    of HSCs. Treatment options for liver fibrosis are
    usually depends on the underlying cause of the
    fibrosis. A healthcare professional can treat the
    underlying liver fibrosis illness conditions, to
    reduce the effects of liver disease.
  • Furthermore, key players in the liver fibrosis
    treatment market are engaged in pre-clinical and
    clinical studies to develop novel treatment
    therapies in liver fibrosis regime. For instance,
    in March 2018, the U.S. FDA granted Orphan Drug
    Designation for PTG-300 a subcutaneous
    injectable developed by Protagonist Therapeutics,
    Inc. The PTG-300 is currently in clinical
    development stage for the potential treatment of
    beta-thalassemia, and can also be used in the
    liver fibrosis treatment.

  • For instance, Gilead Sciences, Inc., in October
    2017, released the Phase II result studies for
    Selonsertib GS-0976 in Nonalcoholic
    Steatohepatitis (NASH) stage F3 liver fibrosis.
    These studies reported that, GS-0976 led to
    significant reductions in concentration of liver
    fat and fibrosis. Moreover, Gilead Sciences also
    contain 18 other pipeline molecules in the liver
    fibrosis treatment, which is further expected to
    boost companys revenue in near future.
  • In April 2017, Tobira Therapeutics, Inc.
    initiated the clinical study to confirm the
    efficacy and safety of cenicriviroc (CVC) for the
    treatment of liver fibrosis in adult patients
    with NASH. The study is expected to complete in
    July 2019.
  • In April 2017, Bristol-Myers Squibb Company
    presented the Phase II clinical trial study of
    BMS-986036 a human fibroblast growth factor. The
    study results reported that BMS-986036 shows
    consistent improvement in liver fat, liver
    injury, and liver fibrosis in patients with
    Nonalcoholic Steatohepatitis (NASH). Increasing
    number of clinical trials are currently in
    process for the treatment of liver fibrosis,
    which are expected to augment the market growth
    over the forecast period.

Global Liver Fibrosis Treatment Market Share (),
By Treatment Type 2018 2026

  • North America market accounted for the largest
    market share, followed by Europe in 2018. This is
    owing to increasing burden of potential risk
    factors leading to liver fibrosis such as
    obesity, type 2 diabetic, metabolic fibrosis,
    alcoholic fibrosis, non-alcoholic steatohepatitis
    (NASH), non-alcoholic fatty liver disease
    (NAFLD), among others. For instance, according to
    the NASH Education Program, 2018 data findings,
    NAFLD is most common chronic liver condition in
    Western population of economies in the Europe and
    the U.S. region as compared to obesity and type 2
    diabetes epidemics. Furthermore, the prevalence
    of NASH is expected to increase by 63 between
    2015 and 2030, leading to NASH become a major
    cause of liver transplantation in the U.S. by
  • Furthermore, according to the World Health
    Organization (WHO), in 2016 more than 1.9
    billion adults, 18 years and older were
    overweight, among which around 650 million were
    obese. According to Organisation for Economic
    Co-operation and Development (OECD) Obesity
    Update 2017 report, obesity levels are expected
    to be particularly high in the U.S., Mexico and
    U.K., where 47, 39 and 35 of the population
    respectively are projected to be obese in 2030.

  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Referance https//

About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions. We are headquartered
    in India, having office at global financial
    capital in the U.S. Our client base includes
    players from across all business verticals in
    over 150 countries worldwide.
  • What We ProvideCustomized Market Research
    AnalysisIndustry Analysis ServicesBusiness
    Consulting ServicesLong Term Engagement
    ModelCountry Specific Analysis

Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt. LTD.Coherent
    Market Insights 1001 4th Ave, 3200 Seattle, WA
    98154, U.S.Phone 1-206-701-6702
  • Email

Thank You
  • Kindly Follow CMI Social Media Profiles for the
    latest Company Updates.
  • Facebook
  • Linkedin
  • Twitter
  • https//